MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial | Publicación